Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors

This study is testing a combination approach for people with cancer that has spread to the liver: using cryoablation (freezing the tumor) alongside two drugs — sintilimab (an immunotherapy) and lenvatinib (a targeted therapy) — to shrink or destroy liver tumors. **You may be eligible if...** - You have any solid tumor that has spread to the liver and cannot be surgically removed - Your liver metastases have progressed after at least one prior treatment - You have at least one measurable tumor in the liver - You are reasonably active (ECOG performance status 2 or better) - Your expected survival is at least 12 weeks - Your blood counts and organ function meet the required minimums **You may NOT be eligible if...** - You have active uncontrolled infections - Your organ function is too poor to tolerate treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.